Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Evaluation of the Safety and Protective Efficacy of a Single Dose of the Live Attenuated Tetravalent Dengue Vaccine TetraVax-DV TV005 to Protect Against Infection With Live, Recombinant DENV-2 (rDEN2∆30-7169) Attenuated Strain in a Dengue Endemic Population in South Asia

NCT05229354 is registered in ClinicalTrials.gov with Beth Kirkpatrick as lead sponsor.

NCT NCT05229354
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05229354 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Evaluation of the Safety and Protective Efficacy of a Single Dose of the Live Attenuated Tetravalent Dengue Vaccine TetraVax-DV TV005 to Protect Against Infection With Live, Recombinant DENV-2 (rDEN2∆30-7169) Attenuated Strain in a Dengue Endemic Population in South Asia
Lead sponsor
Beth Kirkpatrick
Phase
Phase 2
Overall status
Active, not recruiting
Start date
December 11, 2021
Completion date
July 31, 2025
Enrollment
192 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

dengue